Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer

Key Points

• Younger women with ER-positive early-stage breast cancer respond well to targeted therapies, improving overall treatment outcomes.
• Studies indicate improved survival rates of over 15% when tailored therapies are applied in this demographic.
• Observational analysis highlights genetic and hormonal biomarkers that help refine targeted treatment strategies.
• Findings suggest a need for further trials to optimize treatment protocols for this specific population, emphasizing personalized care.